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ABSTRACT
Non-alcoholic fatty liver disease (NAFLD) is liver disorders characterized by 
macrovesicular fatty liver, fibrosis, cirrhosis that not associated with alcohol 
consumption. The prevalence of NAFLD has risen with a pandemic of obesity. 
The increase of free fatty acid (FFA) oxidation will induce endoplasmic 
reticulum stress that cause mitochondrial dysfunction and lead to increase 
reactive oxygen species (ROS) production causing apoptosis of liver cells. The 
aim of  study was to determine the prevalence of FFA in the obese group. This 
was an observational analytical study with cross-sectional design to determine 
the prevalence ratio of FFA in the obese group with NAFLD compared to the 
group without NAFLD. Obese women who fulfill the inclusion and exclusion 
criteria were involved in this study. Five mL venous blood sample was collected 
for the measurement of lipid profile, liver enzyme and FFA. Fatty liver was 
evaluated using abdominal USG. The Chi-square test was used to analyze 
different proportions of FFA between the both groups. Sixty four subjects were 
participated in this study and classified into obese with NAFLD (39 subjects) 
and obese without NAFLD (25 subjects). The prevalence ratio of FFA with cutoff 
value ≥2.66 nmol/mL in the obese group with NAFLD was 4.3 times higher than 
those without NAFLD (95% IC: 3.5 – 42.3; p<0.001). 
ABSTRAK
Non-alcoholic fatty liver disease (NAFLD) adalah gangguan hati yang ditandai 
dengan macrovesicular fatty liver, fibrosis, sirosis dan tanpa dikaitkan 
dengan konsumsi alkohol. Prevalensi NAFLD meningkat bersama pandemik 
obesitas. Peningkatan oksidasi asam lemak bebas (FFA) akan menginduksi 
stres retikulum endoplasma dan mengakibatkan disfungsi mitokondria 
yang menyebabkan peningkatan produksi spesies oksigen reaktif (ROS) dan 
terjadinya apoptosis sel-sel hati. Penelitian ini bertujuan untuk menghitung 
prevalensi FFA pada kelompok obesitas dengan NAFLD. Wanita obesitas yang 
memenuhi kriteria inklusi dan ekslusi dilibatkan dalam penelitian ini. Lima 
mL sampel darah vena dikumpulkan untuk pengukuran profil lipid, enzim hati 
dan FFA. Lemak hati diukur dengan USG pada bagian abdomen. Uji Chi-kuadrat 
digunakan untuk menganalisis perbedaan proporsi dari FFA antara grup 
obesitas dengan NAFLD dan grup obesitas tanpa NAFLD. Sebanyak 64 subjek 
berpartisipasi dalam penelitian ini dan dikelompokkan dalam grup obesitas 
dengan NAFLD (39 subjek) dan grup obesitas tanpa NAFLD (25 subjek). Rasio 
prevalensi FFA dengan nilai cut off  ≥2,66 nmol/mL pada kelompok obesistas 
dengan NAFLD 4,3 kali lebih tinggi dari kelompok obesistas tanpa NAFLD (IK 
95%: 3,5 – 42,3; p<0,001). 
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INTRODUCTION
Non alcoholic fatty liver disease 
(NAFLD) is known as one of the chronic 
liver disorders in the  developing 
countries with the prevalence of 10% 
- 24%.1 Wilson et al.2 reported that this 
disease is strongly correlated to obesity.2 
The highest prevalence of NAFLD was 
reported at 40-49 years old.1 The NAFLD 
may develop into fibrosis or hepatic 
cirrhosis (15-50%) and mortality (10%).3 
Total patients with NAFLD, 5% of them 
has been developing to be hepatic 
cirrhosis in period of 7 years and 1.7% 
died caused by the hepatic cirrhosis.4
The consensus of NAFLD/Non 
Alcoholic Steatohepatitis (NASH) in 
Cebu reported that Indonesia has the 
highest number of sufferers of NAFLD in 
Southeast Asia at 30%, while,  Malaysia 
and Singapore were only 17% and 5%. 
In accordance with the Household 
Health Survey in Indonesia in 2001 and 
2004, there was increased prevalence 
of overweight (body mass index/BMI≥ 
25 - <30) from 11.1-15.5% and obesity 
(BMI≥30) from 2.4% to 3.4%.5
Obesity is a state of excess fat 
accumulation in the body by fatty 
tissue and can cause several diseases. 
The occurrence of obesity in the 
world is increasing as results of the 
lifestyle modernization with increase 
calories, limited physical activities 
and urbanization also determined by 
environmental factor.6
There is a strong relation between 
NAFLD and obesity. Obesity is 
differentiated between central obesity 
(visceral) and peripheral obesity. The 
central obesity is the fat accumulation in 
both subcutaneous abdomen and intra-
abdominal abdomen and also known as 
abdominal obesity. The peripheral obesity 
is the fat accumulation tends to be in the 
lower part of the body in gluteofemoral 
area.7 Examination using abdomen CT-
scan showed that the central obesity 
plays a very essential role towards the 
insulin resistance. This is because the 
central obesity-related to increasing FFA 
as a factor of insulin resistance.8
The increase of FFA oxidation will 
induce endoplasmic reticulum stress 
that  activate the course of inhibitory 
kappa β kinase/nuclear factor kappa 
β(IKK-β/NF-kβ) lead to increase of 
inflammatory cytokine expression 
such as TNF-alpha, interleukin-6 (IL-6), 
interleukin-1β (IL-1β) and activation of 
Kupffer cells. The increase of FFA also 
cause of mitochondrial dysfunction 
and increase of reactive oxygen species 
(ROS) production causing the apoptosis 
of the heparin cells. The accumulation 
of inflammatory mediators in liver 
and apoptosis liver cell can cause  non-
alcoholic steatohepatitis (NASH). Other 
factors that contribute to increased 
FFA in plasma are increased sensitivity 
of fats deposit in the body to effect of 
catecholamine lipolysis and  decrease 
sensitivity to the effect insulin 
antilipolysis on fat tissues that are 
insulin dependent and the bluntness of 
esterification of FFA relying on insulin 
in fat tissue.9 This study was aimed to 
detrmine the prevalence ratio of FFA in 
the obese group with NAFLD compared 
without NAFLD.
MATERIALS AND METHODS
This study was conducted from 
August 2015 to March 2016. The protocol 
of the study was approved by the 
Medical and Health Research Ethics 
Committee, Faculty of Medicine, Public 
Health and Nursing, Universitas Gadjah 
Mada, Yogyakarta. It was an analytical 
observational with cross-sectional 
design. The subjects were obese women 
from an Islamic Study Group, which 
were voluntarily participating in this 
study from Mantup hamlet, Baturetno 
sub-district, Gemawang hamlet and 
Rejodani hamlet, Yogyakarta Special 
Region, Indonesia. Subjects were 
selected in order to fulfil the inclusion 
and exclusion criteria. The inclusion 
criteria included the female aged ≥17 
years old,  obese based on Pacific Asia 
female criteria in accordance with WHO 
with BMI ≥25 kg/m2 diagnosed by USG 
and showed NAFLD and without NAFLD, 
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no record for the consumption of ≥20 
g alcohol/day (2 glasses/day), agreed 
and signed the informed consent. The 
exclusion criteria included the patient 
with the history of hepatitis and other 
diseases that had the equal display of 
USG such as drastic weight reduction, 
drug consumption caused steatosis such 
as steroid, estrogen, calcium-blocker, 
amiodarone, tetracycline, tamoxifen, 
methotrexate, valproic acid, cocaine and 
antivirus. 
The measurement of FFA level 
was conducted using the quantitative 
method of sandwich enzyme 
immunoassay (Qayee-Bio, Shanghai, 
China), lipid profile using automatic 
chemistry analyzer dimension EXL 200 
(Siemens, Germany). The subjects who 
fulfilled the inclusion and exclusion 
criteria were asked to attend at Clinical 
Laboratory Installation of Dr. Sardjito 
General Hospital, Department of Clinical 
Pathology and Medical Laboratory, 
Faculty of Medicine, Public Health and 
Nursing, Universitas Gadjah Mada, 
Yogyakarta and Installation of Radiology, 
Academic Hospital, Universitas Gadjah 
Mada, Yogyakarta at the time agreed 
during the period of specified study.
Data analysis
The data of the characteristic of 
the research subject were presented 
descriptively or as mean and standard 
deviation (SD) if the distribution was 
normal, median and maximum-minimum 
value if the distribution was not normal. 
The continual test of the normality used 
Kolmogorov Smirnov. The test on the 
difference between the two groups was 
conducted using independent t-test or 
Mann Whitney U-test. The analysis of 
different proportion was conducted 
using Chi-square by measuring the 
ratio of the prevalence (RP) with 95% 
CI, p<0.05. The analysis with the curve 
of the receiver operating characteristic 
(ROC) was done to determine the cut off 
value of FFA level. The area under curve 
(AUC) is an area under the curve of ROC 
that can be used to assess the accuracy of 
a diagnosis.
RESULTS
The total of the subjects involved in 
this research was 64 people divided into 
the obese group with NAFLD (39 people) 
and the obese group without NAFLD (25 
people) (TABLE 1).
TABLE 1. The characteristics of the subjects in the obese group with and without NAFLD
Variable Obese with NAFLD Obese without NAFLD p
Age  (mean ± SD years)** 49.12 ± 10.74 49.9 ±11.83 0.79
Abdominal circumference 
[median (min-max) cm] * 103 (101.9-106.5) 103 (101.4–106.9) 0.89
Body Height (mean ± SD cm)** 153.32 ± 6.60 152.37 ± 6.92 0.59
Body Weight (mean ± SD kg)* 73.80 ± 13.47 70.90 ±10.00 0.38
BMI (mean ± SD kg/m2)* 31.40 ± 4.36 30.39 ± 2.94 0.34
Blood pressure [median (min-max)]
•	 Systolic (mmHg) * 128 (121.71-130.59) 126 (121.48-135.78) 0.75
•	 Diastolic (mmHg) * 85 (81.98-88.78) 82.72 (78.2-87.5) 0.36
Note: *Mann Whitney U test;  ** Independent t test
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A significant difference was found 
in the triglyceride and FFA between the 
group of obese with NAFLD rather than 
in the one without NAFLD. There was no 
significant difference regarding age, body 
height, body weight, BMI, abdominal 
circumference, systolic blood pressure, 
diastolic, AST, ALT, total cholesterol, HDL 
cholesterol and LDL cholesterol in the 
obese group with NAFLD and without 
NAFLD (TABLE 2). 
The receive operation curve (ROC) 
determined cut off levels of FFA was 
2.66 nmol/mL by the area under curve 
(AUC) value of 0.78. At the cut off value 
was obtained a sensitivity of 80% and a 
specificity of 64%.
TABLE 2. Profile of the liver function test on obese group with and without NAFLD
Variable Obese with NAFLD Obese without NAFLD p
FFA (mean ± SD nmol/mL)* 3.22 ± 0.69 2.50 ± 0.60 <0.001
AST [median (min-max) 
IU/L]* 30(16-40) 21(12-45) 0.07
ALT (mean ± SD IU/L)** 26.87±11.59 19.95±7.37 0.01
Total cholesterol [median 
(min-max) mg/dL]* 232(195-312) 252(174-320) 0.44
HDL cholesterol [median 
(min-max) IU/L]* 40(18-59) 36(25-68) 0.9
LDL cholesterol (mean ±SD 
mg/dL)** 191.18±51.33 173±37.68 0.16
Triglyceride cholesterol 
[median (min-max) mg/dL]* 197(132-388) 145(103-248) 0.001
Note: *Mann Whitney U test;  ** Independent t test
The prevalence ratio of the increase 
of FFA in this research was 4.3 (2.1 – 
21.7) with p value <0.0001. It can be 
interpreted that the increase of FFA 
≥2.66 nmol/mL had the risk of 4.3 times 
higher than the occurrence of NAFLD. 
From the population of samples studied, 
the confidence interval 95% (CI 95%) was 
between 2.1 – 21.7, thus the increase of 
FFA can be used as a good indication of 
the occurrence of NAFLD on the obese 
population (TABLE 3).
TABLE 3. The prevalence ratio of the increase of FFA on NAFLD of 
obese population
Prevalence ratio 95% CI p
Increasing FFA  4.30 2.1 – 21.7 <0.0001
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DISCUSSION 
NAFLD is indicated with the 
accumulation of the triglyceride, 
formed from the esterification of FFA 
and glycerol in the hepatocyte. FFA 
emerged in the liver from three different 
sources; those are lipolysis (hydrolysis 
of FFA and glycerol from triglyceride) 
in the adipose tissues, food sources and 
de novo lipogenesis. The genetic factor 
contributed to the regulation of de novo 
lipogenesis for the existence of the 
mutation in the nuclear transcription 
factor.10
Steatosis associated with chronic 
liver inflammation, partly mediated 
by activation of IKK-β/NF-κβ signaling. 
Increased activity of NF-κβ associated 
with liver expression of inflammatory 
cytokines such as TNF-α, IL-6 andIL-
1β, and activation of Kupffer cells.11 
Pathway of IKK-β / NF-κβ in hepatocytes 
can also be activated directly by the FFA, 
further mechanisms of central obesity 
increased supply of FFA liver can cause 
inflammation. In addition, the data 
suggest that inflammation and activation 
of NF-κB can trigger carcinogenesis 
and chronic inflammation associated 
with hepatic steatosis can play a key 
role in the development of carcinoma 
hepatosellular.11
Ruhl et al.12 reported that individuals 
with obesity/overweight and central fat 
distribution will evolve into NAFLD. The 
elevated of the prevalence of NAFLD 
consistent with an increasing of BMI. 
The results showed systolic and diastolic 
blood pressure to be higher in the obese 
group with NAFLD. The population of 
NAFLD with diabetes compared with 
NAFLD population without diabetes, p 
value of systolic and diastolic consecutive 
participated 0.417 and 0.709, although 
not found a statistically significant 
difference. Increased blood pressure 
is strongly associated with obesity and 
insulin resistance.13
Cytokines produced by adipocytes 
to stimulate lipolysis, which will lead to 
increased synthesis of FFA. Increased 
FFA cause an increased in production of 
triglycerides by the liver and increase 
hepatic VLDL secretion. Triglycerides 
increased in circulation resulting 
lipoprotein bring more triglycerides and 
less HDL.14
This study was obtained difference 
of mean levels of FFA in subjects NAFLD 
compared without NAFLD. These results 
are consistent with previous studies 
conducted by Purnama et al.15 in which 
the FFA level in the obese group with 
diabetes mellitus (0.996±0.296 mE) 
higher than the obese group without 
diabetes mellitus (0.567±0.122 mE).15
In this study the ALT levels increased 
in the obese group with NAFLD 
compared without NAFLD. This is similar 
to research conducted by Paola et al.16 
ALT is more specific than AST to predict 
liver damage. A marker AST/ALT ratio 
as a screening occurrence of NAFLD 
prevalence is very low with the result of 
15-20%, but if AST/ALT combined with 
abdominal ultrasound will produce a 
higher prevalence of NAFLD (20-46%).17
The usual observed biochemical 
pattern in hepatic steatosis due to NAFLD 
is of increased levels of transaminases, 
with ALT levels exceeding those of AST. 
This classical pattern is particularly 
useful in differentiating between hepatic 
steatosis from NAFLD and alcoholic 
liver injury, with the latter normally 
associated with a high AST:ALT ratio. The 
progression of hepatic steatosis to NASH 
and associated hepatic fibrosis, however, 
AST levels increase with a resultant 
rise in the AST:ALT ratio.18 The degree 
of improvement in aminotransferase 
levels cannot be used as a predictive 
factor. Although in some cases the 
levels of ALT are higher than levels of 
AST, AST levels may be higher than ALT 
levels, especially when there cirrhosis.19 
Research conducted by Bellentani 55% 
of patients with NAFLD had normal 
aminotransferase levels. This shows that 
the liver enzyme is not a good marker for 
the diagnosis of NAFLD.20
The result of this study different 
from research conducted by Purnama et 
al.15 subject of NAFLD with and without 
DM obtained OR 12.391 CI 95% with 
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p<0.001. The obese subject also suffered 
DM, it would increase the prevalence of 
the occurrence of NAFLD. It was because 
of the resistance of the insulin causing 
the occurrence of the increase of FFA. 
The limitations of the study such 
as the width of CI 95% 2.1 to 21.7. 
It is probably caused by visceral fat 
distribution varies, the measurement 
of visceral fat levels can be done by 
checking dual X-ray absorptiometry 
(DXA) scan, this examination is expensive 
and only certain hospitals that have such 
facilities. Another limitation of this study, 
was not examined genetic factors as well 
as physical activity. Genetic testing of 
the genes that affect the regulation of 
de novo lipogenesis due to mutations 
in the nuclear transcription factor. 
Some of these receptors, among others 
sterol regulatory element-binding factor 
(SREBF) 1, liver X receptor (LXR) alpha, 
farnesoid X receptor (FXR), peroxisome 
proliferator-activated receptors (PPAR) 
gamma, PPAR Alpha. In additional 
the design of this study is still a cross-
sectional design so it cannot explain the 
temporal relationship (causal), this can 
lead to bias because the data was only 
describing the current state of research.
CONCLUSIONS
The prevalence ratio of FFA in the 
obese group with NAFLD significantly 
increased 4.3 times compared to the 
group without NAFLD.
ACKNOWLEDGEMENTS
We offer special thanks to Mr. 
Untung who helped us act as the expert 
technical assistance.
REFERENCES
1. Sey AV. Nonalcoholic fatty liver 
disease: epidemiology and diagnosis. 
Hepatology 2003; 37(4):917-23.
https://doi.org/10.1053/jhep.2003.50161
2. Salgado JW, Santos SJ, Sankarankutty 
KA, De Castro SO. Nonalcoholic fatty 
liver disease and obesity. Acta Cir 
Bras 2006; 21:72-8.
ht tps : / /do i .org /10 .1590 /S0102-
86502006000700017
3. Sears, D. Fatty liver. Available at: 
http://www.emedicine.com. Acessed 
on: Juni 2007.
4. Daimon M, Oizumi T, Saitoh T, 
Kameda W, Hirata A, Yamaguchi 
H, et al. Decreased serum levels of 
adiponectin are a risk factor for the 
progression to type 2 diabetes in the 
Japanese population. Diabetes Care 
2003; 26(7):2015-20.
https://doi.org/10.2337/diacare.26.7.2015
5. Household Health Survey. Basic 
health status RISKESDAS of Indonesia. 
Jakarta: Departement of Health, 
Republic of Indonesia. 2004.
6. Dietz WH. The obesity epidemic 
in young children. BMJ 2001; 
322(7282):313-4.
https://doi.org/10.1136/bmj.322.7282.313
7. Aldahl W, Goldstein BJ, Haffner SM. 
Insulin resistance: implications 
for metabolic and cardiovascular 
diseases. Curr Diab Rep 2003; 3:293.
8. Cheng AY, Fantus IG. Oral 
antihyperglycemic therapy for type 
2 diabetes mellitus. CMAJ 2005; 
172(2):213-26.
https://doi.org/10.1503/cmaj.1031414
9. Boden G, Shulman G. Free fatty 
acid in obesity and type 2 diabetes: 
defining their role in the development 
of insulin resistance and beta cell 
dysfunction. Eur J Clin Invest 2002; 
32(3):14-23.
https://doi.org/10.1046/j.1365-2362.32.s3.3.x
10. Postic C, Jean G. Contribution of the 
novo fatty acid synthesis to hepatic 
steatosis and insulin resistence: 
lessons from genetically engineered 
mice. J Clin Invest 2008; 118(3):829-38.
https://doi.org/10.1172/JCI34275
11. Day CP. Pathogenesis of steatohepatitis. 
Best Pract & Res Clin Gastroenterol 
2002; 5:663-78.
https://doi.org/10.1053/bega.2002.0333
12. Ruhl CC, Everhart JE. Fatty liver 
indices in the multiethnic united 
states national health and nutrition 
examination survey. Aliment 
Pharmacol Ther 2015; 41(1):65-76.
151
Purnamaningsih SM, et al.,  Prevalence ratio of free fatty...
http://dx.doi.org/10.1111/apt.13012
13. Adam JMF. Metabolic syndrome: 
definition, epidemiology and 
diagnosis criteria. Obesity and 
metabolic syndrome 2006; 92-100.
14. Jensen MD. Adipose tissue as an endocrine 
organ: implications of its distribution on 
free fatty acid metabolism. Eur Heart J 
2006; 8: B13-B19.
https://doi.org/10.1093/eurheartj/sul003
15. Purnama B, Maduseno S, Nurdjanah 
S, Ratnasari N, Senorita H, Asdie RH. 
The risk factors of non-alcoholic fatty 
liver disease prevalence in obesity 
with or without diabetes mellitus. J. 
Gastroenterol 2009; 10(1).
16. Paola PS, Fernando B, Maryann 
M, Romina L, Biernacki D, Orsak 
B, Sreevidya S. High prevalence 
of nonalcoholic fatty liver disease 
in patients with type 2 diabetes 
mellitus and normal plasma amino 
transferase levels. J Clin Endocrinol 
Metab 2015; 100(6):2231-8.
https://doi.org/10.1210/jc.2015-1966
17. Misra A, Khurana L. Obesity and the 
metabolic syndrome in developing 
countries. J Clin Endocrinol Metab 
2008; 93(11 Suppl 1):S9-30.
https://doi.org/10.1210/jc.2008-1595
18. Sattar N, Forrest E, Preiss D. Non-
alcoholic fatty liver disease. BMJ 
2014; 349:g4596.
https://doi.org/10.1136/bmj.g4596
19. Salt WB. Nonalcoholic fatty liver 
disease (NAFLD): a comprehensive 
review. J Insur Med 2004; 36(1):27-41.
20. Bellentani S, Scaglioni F, Marino M, 
Bedogni G. Epidemiology of non-
alcoholic fatty liver disease. Dig Dis 
2010; 28(1):155-61.
https://doi.org/10.1159/000282080
